84-3175-90 ［取扱停止］KIRR3, CT (KIRREL3, KIAA1867, NEPH2, Kin of IRRE-like protein 3, Kin of irregular chiasm-like protein 3, Nephrin-like protein 2) (MaxLight 650) 100ul 037468-ML650
84-3175-90 ［取扱停止］KIRR3, CT (KIRREL3, KIAA1867, NEPH2, Kin of IRRE-like protein 3, Kin of irregular chiasm-like protein 3, Nephrin-like protein 2) (MaxLight 650) 100ul 037468-ML650
MaxLight™650 is a new Far-IR stable dye conjugate comparable to Alexa Fluor™647, DyLight™649, Cy5™ and offers better labeling efficiency, brighter imaging and increased immunodetection.
KIRR3 is a member of the nephrin-like protein family.
These proteins are expressed in fetal and adult brain, and also in podocytes of kidney glomeruli.
The cytoplasmic domains of these proteins interact with the C-terminus of podocin, also expressed in the podocytes, cells involved in ensuring size- and charge-selective ultrafiltration.
Mutations in this gene are associated with mental retardation autosomal dominant type 4 (MRD4).
Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Applications:Suitable for use in Western Blot, FLISA
Storage and Stability:Store product at 4°C in the dark.
DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid.
Dilute required amount only prior to immediate use.
Further dilutions can be made in assay buffer.
Caution: MaxLight™650 conjugates are sensitive to light.
For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Note: Applications are based on unconjugated antibody.
仕様
Size：100ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by Protein A affinity chromatography.
Form：Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight™650.
Specificity：Human
Isotype：IgG
Calc Applications Abbrev：FLISA WB
Calc Crossreactivity：Hu
Immunogen：KIRR3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 596~626 amino acids from the C-terminal region of human KIRR3.
